{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:11:05Z","timestamp":1792181465731,"version":"4.4.0"},"reference-count":16,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2007,6,19]],"date-time":"2007-06-19T00:00:00Z","timestamp":1182211200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2007,9]]},"abstract":"<jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Lifelong adherence to a strict gluten\u2010free diet is the cornerstone of coeliac disease treatment. Elucidation of disease pathogenesis has created opportunities for novel therapeutic approaches to coeliac disease. AT\u20101001 is an inhibitor of paracellular permeability whose structure is derived from a protein secreted by\n                      <jats:italic>Vibrio cholerae<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To determine the safety and tolerability of 12\u2003mg doses of AT\u20101001 in coeliac disease subjects challenged with gluten.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>An in\u2010patient, double\u2010blind, randomized placebo\u2010controlled safety study utilizing intestinal permeability, measured via fractional excretions of lactulose and mannitol, as an exploratory measure of drug efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Compared to placebo, no increase in adverse events occurred in patients exposed to AT\u20101001. Following acute gluten exposure, a 70% increase in intestinal permeability was detected in the placebo group, while none was seen in the AT\u20101001 group. Interferon\u2010\u03b3 levels increased in four of seven patients (57%) of the placebo group, but only in four of 14 patients (29%) of the AT\u20101001 group. Gastrointestinal symptoms were more frequently detected in the placebo group when compared to the AT\u20101001 group (\n                      <jats:italic>P<\/jats:italic>\n                      \u2003=\u20030.018).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>AT\u20101001 is well tolerated and appears to reduce intestinal barrier dysfunction, proinflammatory cytokine production, and gastrointestinal symptoms in coeliacs after gluten exposure.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/j.1365-2036.2007.03413.x","type":"journal-article","created":{"date-parts":[[2010,7,23]],"date-time":"2010-07-23T08:04:13Z","timestamp":1279872253000},"page":"757-766","source":"Crossref","is-referenced-by-count":222,"title":["The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT\u20101001 in coeliac disease subjects: a proof of concept study"],"prefix":"10.1111","volume":"26","author":[{"given":"B. M.","family":"PATERSON","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. M.","family":"LAMMERS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. C.","family":"ARRIETA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"FASANO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. B.","family":"MEDDINGS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,6,19]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)13803-2"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2005.02.017"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.4.2512"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2005.05.001"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2005.12.1186"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.3700050"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.52.2.218"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1080\/00365520500235334"},{"key":"e_1_2_6_10_2","doi-asserted-by":"crossref","first-page":"4435","DOI":"10.1242\/jcs.113.24.4435","article-title":"Human zonulin, a potential modulator of intestinal tight junctions","volume":"113","author":"Wang W","year":"2000","journal-title":"J Cell Sci"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.1997.v112.pm9041245"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.71.4.1897-1902.2003"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0500178102"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0928-8244(03)00144-5"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpg.2005.01.001"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2005.086637"},{"key":"e_1_2_6_17_2","first-page":"1032","article-title":"Myosin IXB variant increases the risk of celiac disease and points toward a primary intestinal barrier defect","volume":"12","author":"Monsour A","year":"2005","journal-title":"Nat Genet"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2007.03413.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2007.03413.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T18:02:06Z","timestamp":1697220126000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2007.03413.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6,19]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007,9]]}},"alternative-id":["10.1111\/j.1365-2036.2007.03413.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2007.03413.x","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1091061.544445","asserted-by":"object"}]},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,6,19]]}}}